Dana-Farber Cancer Institute Selects Vibrent Health’s Next-Generation Digital Health Research Platform to Enable Early Detection for the Prevention of Multiple Myeloma
The PROMISE Study launches novel data collection, patient engagement, eConsent and researcher tools using Vibrent’s platform FAIRFAX, Va.--(BUSINESS WIRE)--Multiple myeloma is a cancer of the plasma cells in bone marrow that affects more than 30,000 n...